2025
Capacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study
Matheny M, Perkins A, Rieger-Christ K, Ross J, Mao J, Sedrakyan A, Shah N, Winter R, Reynolds W, Mourtzinos A, Schulz W, Bartlett V, Solotke M, Pandya S, Aryal S, Cho A, Frankenberger E, Park D, Bostrom D, Robbins S, Yustein A, Chughtai B, Trabuco E. Capacity assessment for EHR-based medical device post-market surveillance for synthetic mid-urethral slings among women with stress urinary incontinence: a NEST consortium study. BMJ Surgery Interventions & Health Technologies 2025, 7: e000193. PMID: 39949784, PMCID: PMC11822424, DOI: 10.1136/bmjsit-2023-000193.Peer-Reviewed Original ResearchElectronic health record dataElectronic health recordsHealth systemStress urinary incontinenceSynthetic mesh implantsTertiary care academic medical centerSurgical approachManual chart reviewChart reviewAcademic medical centerMedical device surveillanceHealth recordsAdverse event surveillanceMesh implantationUrinary incontinenceDuration of surveillanceAscertainment rateMid-urethral sling (MUSOutcome measuresSynthetic mid-urethral slingsTreat stress urinary incontinenceDetermination of surgical approachEvent surveillanceRetrospective observational studyMedical CenterP-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
Kumar P, Rolle C, Emu B, Henry Z, Martorell C, McKinnon J, Slim J, Cash R, Anstett K. P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics. Open Forum Infectious Diseases 2025, 12: ofae631.763. PMCID: PMC11778372, DOI: 10.1093/ofid/ofae631.763.Peer-Reviewed Original ResearchJournal of Antimicrobial ChemotherapyBaseline characteristicsViral loadMultidrug resistanceAntimicrobial chemotherapyCohort 2Maintenance of virologic suppressionHigher HIV viral loadClinical outcomes of patientsExposure to antiretroviralsGenotypic sensitivity scoreCD4 cell countHIV viral loadCD4 T cellsOutcomes of patientsLong-term efficacyRetrospective observational studyHigh viral loadLong-term useVirologic suppressionInfusion reactionsStudy designT cellsSafety profileClinical outcomes
2024
Increasing patient viewership of complex imaging reports: The paradox of the Cures Act
Amin K, Davis M, Naderi A, Forman H. Increasing patient viewership of complex imaging reports: The paradox of the Cures Act. Clinical Imaging 2024, 119: 110398. PMID: 39756146, DOI: 10.1016/j.clinimag.2024.110398.Peer-Reviewed Original ResearchConceptsElectronic health recordsCentury Cures ActCures ActImprove patient experienceRadiology reportsReading grade levelPatient experienceHealth recordsHealth informationRecommended levelsRetrospective observational studyObservational studyPatientsViewing probabilityRadiologyOddsHealthYearsIncrease viewershipReportsGrade levelModalitiesProvisionAccuracy of a Rapid-Response EEG's Automated Seizure-Burden Estimator
Sheikh Z, Dhakar M, Fong M, Fang W, Ayub N, Molino J, Haider H, Foreman B, Gilmore E, Mizrahi M, Karakis I, Schmitt S, Osman G, Yoo J, Hirsch L. Accuracy of a Rapid-Response EEG's Automated Seizure-Burden Estimator. Neurology 2024, 104: e210234. PMID: 39724534, DOI: 10.1212/wnl.0000000000210234.Peer-Reviewed Original ResearchConceptsElectrographic status epilepticusNegative predictive valueStatus epilepticusTreat nonconvulsive status epilepticusPredictive valueCo-primary outcome measuresNonconvulsive status epilepticusPositive predictive valueRetrospective observational studyClass II evidenceLow-to-moderate sensitivityLimited-resource settingsII evidenceTriage patientsObservational studyPatientsRegional hospitalOutcome measuresExpert reviewEpilepticusScreening toolCommunity hospitalBurden estimatesEEGPPVMechanisms of Repair Failure After Mitral Valve Repair Using Chordal Replacement
Lang M, Feirer N, Voss B, Geirsson A, Amabile A, Krane M, Vitanova K. Mechanisms of Repair Failure After Mitral Valve Repair Using Chordal Replacement. The Annals Of Thoracic Surgery 2024, 119: 362-369. PMID: 39603581, DOI: 10.1016/j.athoracsur.2024.10.029.Peer-Reviewed Original ResearchMechanisms of repair failureMitral valve repairMitral valve replacementMitral valve sclerosisDegenerative mitral regurgitationChordal replacementValve repairMitral regurgitationRe-repairRepair failureTechnical failureIsolated mitral valve repairCases of mitral valve replacementTranscatheter edge-to-edge repairCases of technical failureEdge-to-edge repairMitral valve reoperationGerman Heart Center MunichRetrospective observational studyValve reoperationValve replacementRe-reoperationMitral valveReoperationFollow-upKidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G, Deng Y, Ross J, Mickelson M, McCoy R. Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal Of The American Society Of Nephrology 2024, 20: 206-217. PMID: 39729347, PMCID: PMC11835155, DOI: 10.2215/cjn.0000000587.Peer-Reviewed Original ResearchSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2Dipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Dipeptidyl peptidase-4Receptor agonistsPrimary composite outcomeKidney replacement therapyChronic kidney diseaseComposite outcomeSecondary composite outcomeType 2 diabetesGLP-1 receptor agonist therapyCVD riskCardiovascular diseaseModerate CVD riskPrescribed glucose-lowering agentsBaseline CVD riskHigh-risk patientsAssociated with risk reductionCKD stage 3Retrospective observational studyGlucose-lowering agentsModerate cardiovascular riskRecent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C, de Havenon A. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. BMJ Open Diabetes Research & Care 2024, 12: e004431. PMID: 39366717, PMCID: PMC11459310, DOI: 10.1136/bmjdrc-2024-004431.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGLP-1 RAsAtherosclerotic cardiovascular diseaseGLP-1Type 2 diabetesIncident useGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCardiovascular diseasePrevalence of atherosclerotic cardiovascular diseaseASCVD diagnosisProportion of patientsRetrospective observational studyNested cohort studyReceptor agonistsSGLT2i useAnalysis of cross-sectional dataSodium-glucoseCohort studyPatient numbersObservational studyPatientsPrevalent useCross-sectional dataT2DCLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.Peer-Reviewed Original ResearchPer-patient per-monthPer-patient per-month costsChronic lymphocytic leukemiaBruton tyrosine kinase inhibitorFirst-line treatmentTyrosine kinase inhibitorsLymphocytic leukemiaMonths 0Kinase inhibitorsHealthcare costsCLL/small lymphocytic lymphomaFixed-duration treatmentFirst-line therapyOff-treatment periodMonths post-indexMonths pre-indexRetrospective observational studyClinical trial enrollmentUS health planCommercially insured patientsLymphocytic lymphomaPrimary cancerFirst-linePost-indexIbrutinib697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of non-melanoma skin cancerModerate-to-severe diseaseAtopic dermatitisNon-AD cohortRheumatoid arthritisControl cohortNon-melanoma skin cancer riskModerate-to-severe atopic dermatitisNon-melanoma skin cancer incidenceMultivariate Cox proportional hazards modelSkin cancerModerate-to-severe ADCohort entry dateSquamous cell carcinomaMatched control cohortIntermittent sun exposureFollow-up timeNon-AD controlsRetrospective observational studyCox proportional hazards modelsEffect of disease activityPopulation-based studyProportional hazards modelClinformatics Data MartSyndromic Surveillance Tracks COVID-19 Cases in University and County Settings: Retrospective Observational Study
Wass L, Hoare D, Smits G, Osman M, Zhang N, Klepack W, Parrilla L, Busche J, Clarkberg M, Basu S, Cazer C. Syndromic Surveillance Tracks COVID-19 Cases in University and County Settings: Retrospective Observational Study. JMIR Public Health And Surveillance 2024, 10: e54551. PMID: 38952000, PMCID: PMC11220726, DOI: 10.2196/54551.Peer-Reviewed Original ResearchConceptsCOVID-19-like illnessSyndromic surveillanceCounty Health DepartmentSARS-CoV-2 test positivityCounty settingsMiddle-income countriesLow-resource settingsCounty levelReport surveillance dataHealth departmentsTest positivity rateLinear regression modelsPositive test rateTesting ratesCOVID-19 casesSelf-reportSymptom reportingCOVID-19 riskCOVID-19 testingCOVID-19Negative binomial modelRetrospective observational studyTest positivityCOVID-19 surveillanceObservational studyOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageSustentaculum fracture fixation with lateral plate or medial screw fixation are equivalent
Roytman G, Salameh M, Rizzo S, Dhodapkar M, Tommasini S, Wiznia D, Yoo B. Sustentaculum fracture fixation with lateral plate or medial screw fixation are equivalent. Injury 2024, 55: 111532. PMID: 38614015, DOI: 10.1016/j.injury.2024.111532.Peer-Reviewed Original ResearchSubtalar jointCadaveric anklesSustentaculum tali fracturesFresh-frozen cadaveric anklesT-testAssess patient outcomesPaired t-testUn-paired t-testAnkle modelAnkleRight ankleLeft ankleMid-tibiaPatient outcomesRetrospective observational studyScrew fixationObservational studyMethod of fixationFracture fixationBiomechanical functionMedial approachBody massFixation methodsInterosseous ligamentNo significant differenceSelective Use of CT Fractional Flow at a Large Academic Medical Center: Insights from Clinical Implementation after 1 Year of Practice.
Randhawa M, Takigami A, Thondapu V, Ranganath P, Zhang E, Parakh A, Goiffon R, Baliyan V, Foldyna B, Lu M, Tower-Rader A, Meyersohn N, Hedgire S, Ghoshhajra B. Selective Use of CT Fractional Flow at a Large Academic Medical Center: Insights from Clinical Implementation after 1 Year of Practice. Radiology Cardiothoracic Imaging 2024, 6: e230073. PMID: 38573127, PMCID: PMC11056747, DOI: 10.1148/ryct.230073.Peer-Reviewed Original ResearchConceptsRate of invasive coronary angiographyCoronary CTAInvasive coronary angiographyCoronary CT angiographyCT-FFR analysisPercutaneous coronary interventionHeart rate controlCT-FFRRetrospective observational studyFractional flow reserveCT angiographyDual-source coronary CT angiographyCT fractional flow reserveFlow reserveObservational studyCoronary bypass graftingEarly diastolic periodBeats per minuteCoronary angiographyPhysician's discretionChart reviewClinical outcomesBypass graftingCTA acquisitionAcademic medical centerClinical phenotypes among patients with normal cardiac perfusion using unsupervised learning: a retrospective observational study
Miller R, Bednarski B, Pieszko K, Kwiecinski J, Williams M, Shanbhag A, Liang J, Huang C, Sharir T, Hauser M, Dorbala S, Di Carli M, Fish M, Ruddy T, Bateman T, Einstein A, Kaufmann P, Miller E, Sinusas A, Acampa W, Han D, Dey D, Berman D, Slomka P. Clinical phenotypes among patients with normal cardiac perfusion using unsupervised learning: a retrospective observational study. EBioMedicine 2024, 99: 104930. PMID: 38168587, PMCID: PMC10794922, DOI: 10.1016/j.ebiom.2023.104930.Peer-Reviewed Original ResearchMyocardial infarctionMyocardial perfusion imagingBlood InstituteNational HeartPharmacologic stressExternal testing cohortNormal imaging resultsRetrospective observational studyCoronary artery diseasePrevious myocardial infarctionRisk of deathNormal perfusion scanBritish Heart FoundationNational InstituteCluster 4 patientsDistinct phenotypesCardiovascular riskArtery diseaseRisk stratificationPerfusion scanNormal perfusionImaging featuresNormal scansMPI patientsHeart FoundationSafety and Efficacy of Combining Left Atrial Appendage Occlusion With Another Cardiac Procedure
Ismayl M, Ahmed H, Freeman J, Alkhouli M, Lakkireddy D, Goldsweig A. Safety and Efficacy of Combining Left Atrial Appendage Occlusion With Another Cardiac Procedure. JACC Cardiovascular Interventions 2024, 17: 262-273. PMID: 38267141, DOI: 10.1016/j.jcin.2023.10.017.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionLength of stayCardiac proceduresIn-hospital mortalityAppendage occlusionOutcomes of left atrial appendage occlusionConcomitant transcatheter aortic valve replacementVascular injuryTranscatheter aortic valve replacementConcomitant procedure groupConcomitant cardiac proceduresAortic valve replacementOdds of MACEAcute kidney injuryNational Inpatient Sample databaseRetrospective cohort studyRetrospective observational studyAdverse cardiovascular eventsInpatient Sample databaseOdds of strokeFlutter ablationValve replacementBlood transfusionClinical outcomesHeart block
2023
Association of Neighborhood-Level Socioeconomic Factors With Delay to Hospital Arrival in Patients With Acute Stroke
Forman R, Okumu R, Mageid R, Baker A, Neu D, Parker R, Peyravi R, Schindler J, Sansing L, Sheth K, de Havenon A, Jasne A, Narula R, Wira C, Warren J, Sharma R. Association of Neighborhood-Level Socioeconomic Factors With Delay to Hospital Arrival in Patients With Acute Stroke. Neurology 2023, 102: e207764. PMID: 38165368, PMCID: PMC10834135, DOI: 10.1212/wnl.0000000000207764.Peer-Reviewed Original ResearchConceptsEmergency department arrival timesEmergency medical servicesLate presentationAcute ischemic stroke therapyYale-New Haven HospitalGuidelines-Stroke registryNeighborhood-level socioeconomic factorsPatient-level factorsRetrospective observational studyIschemic stroke therapyMixed-effects logistic regression modelNon-white patientsNon-white raceUnivariate logistic regressionNew Haven HospitalLogistic regression modelsHospital presentationTreatment ineligibilityStroke RegistryAcute strokeHospital arrivalStroke therapyUnivariate analysisObservational studyPatientsConsecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit
Allen C, Streiff M, Naik R, Knauert M, Goshua G. Consecutive Inpatient Hematology Consultation Service Utilization across 11 Years in the Medical Intensive Care Unit. Blood 2023, 142: 2323. DOI: 10.1182/blood-2023-184891.Peer-Reviewed Original ResearchMedical intensive care unitIntensive care unitHematology consultationCare unitHematology consultMICU admissionLymphoproliferative disordersHematologic malignanciesMalignant hematologyService utilizationConsecutive patients 18 yearsHospital discharge statusPatients 18 yearsCritical care managementRetrospective observational studySingle academic centerPlasma cell dyscrasiaQuality improvement metricsDay of consultationHigh clinical volumeService needsDescriptive statisticsExpedient careICU consultationBaseline demographicsReal-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study
Theprungsirikul P, Liu Y, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma: A Retrospective Observational Study. Blood 2023, 142: 7364. DOI: 10.1182/blood-2023-186985.Peer-Reviewed Original ResearchFront-line treatmentBone marrow plasma cellsCommunity practice settingsR-ISS stageECOG performance statusRetrospective observational studyPerformance statusTransplant eligibilityPractice settingsCytogenetic abnormalitiesBone lesionsInsurance typeObservational studyTreatment responseEastern Cooperative Oncology Group performance statusInternational Myeloma Working Group criteriaYale New Haven Health SystemInternational Staging System stageRefractory multiple myeloma patientsUnfavorable-risk cytogeneticsGood partial responseFront-line therapyCD38 monoclonal antibodyMultiple myeloma patientsBetter treatment responseClinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy
Abu-Sbeih H, Tang T, Ali F, Ma W, Shatila M, Luo W, Tan D, Tang C, Richards D, Ge P, Thomas A, Wang Y. Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy. Cancers 2023, 15: 3160. PMID: 37370770, PMCID: PMC10296205, DOI: 10.3390/cancers15123160.Peer-Reviewed Original ResearchArgon plasma coagulationRadiation therapyMedical managementAPC treatmentSingle tertiary cancer centerRadiation-induced colitisManagement of AcuteNon-bloody diarrheaRetrospective observational studyTertiary cancer centerCancer patients' qualityLogistic regression analysisClinical characteristicsEndoscopic therapySymptom onsetPredominant symptomClinical featuresEndoscopic characteristicsPatients' qualityCancer CenterClinical variablesBloody diarrheaCancer patientsFemale sexFrequent findingGlucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
Cooper D, Ramachandra R, Ceban F, Di Vincenzo J, Rhee T, Mansur R, Teopiz K, Gill H, Ho R, Cao B, Lui L, Jawad M, Arsenault J, Le G, Ramachandra D, Guo Z, McIntyre R. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal Of Psychiatric Research 2023, 164: 80-89. PMID: 37331261, DOI: 10.1016/j.jpsychires.2023.05.041.Peer-Reviewed Original ResearchConceptsGLP-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsIncident depressionDiabetes mellitusReceptor agonistType 2 diabetes mellitusRetrospective observational studyPubMed/MEDLINEEnglish-language articlesHigh interstudy heterogeneityGoogle Scholar databasesPaucity of literatureGlycemic controlNeuroprotective effectsAntidepressant propertiesNeuroprotective potentialInterstudy heterogeneityObservational studyPatientsSystematic reviewAgonistsMellitusScholar databasesProtective factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply